Farxiga, a treatment to reduce the risk of heart failure in patients with type 2 diabetes has been approved by the FDA.
List view / Grid view
Filter the results
Farxiga (dapagliflozin) has been given Fast Track designation by the FDA to reduce the risk of cardiovascular death.
Fast Track designation has been granted to Farxiga to prevent heart and kidney failure in patients with chronic kidney disease.